OncLive TV

Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.

Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.

Joseph Franses, MD, PhD, discusses treatment considerations for hepatocellular carcinoma that progresses after first-line therapy.

Marc Machaalani, MD, discusses how inhibition of AXL and c-Met may prevent acquired resistance to c-Met inhibitors in renal cell carcinoma.

Craig Eckfeldt, MD, PhD, discusses how improved minimal residual disease testing methods have impacted the acute myeloid leukemia treatment paradigm.

Alicia Morgans, MD, MPH, discusses data from the ARAMIS trial showing the association between PSA levels and radiological progression in nmCRPC.

Alfred L. Garfall, MD, MS, discusses updated safety data for teclistamab in relapsed/refractory multiple myeloma.

Razane El Hajj Chehade, MD, discusses the association between different histologic subtypes in renal cell carcinoma and the risk of developing immune-related adverse effects.

Mark Juckett, MD, discusses ways the treatment paradigm has changed for patients with relapsed/refractory acute myeloid leukemia.

Coral Olazagasti, MD, discusses disparities in lung cancer screening rates between Hispanic and non-Hispanic White survivors of head and neck cancer.

Barbara Jane O’Brien, MD, discusses expanding clinical trial enrollment criteria to include patients with HER2-positive breast cancer brain metastases.

Tycel Phillips, MD, discusses the evolution of treatment for patients with myelodysplastic syndromes, highlighting the future of this treatment paradigm.

Giuseppe Curigliano, MD, PhD, discusses the implications of treatment with T-DXd in HR+, HER2-low or HER2-ultralow metastatic breast cancer.

Timothy Hughes, MD, MBBS, FRACP, FRCPA, on safety data for asciminib in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia.

Andrew Davis, MD, discusses the use of antibody-drug conjugates in breast cancer, highlighting recent updates with these agents in the treatment paradigm.

Noa Biran, MD, discusses the impact of the IMROZ trial in the treatment of patients with newly diagnosed, transplant-ineligible multiple myeloma.

Komal Jhaveri, MD, FACP, discusses the evolution of antibody-drug conjugates for patients with HER2-positive, HER2-low or HER2-ultralow metastatic breast cancer.

Antonio Cigliola, MD, discusses the phase 2 SURE-01 study of neoadjuvant sacituzumab govitecan in muscle-invasive bladder cancer.

Brian I. Rini, MD, FASCO discusses findings from an exploratory analysis of the phase 3 KEYNOTE-426 study.

Grzegorz S. Nowakowski, MD, discusses the significance of the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.

Adrienne G. Waks, MD, discusses implications of the potential use of first-line T-DXd in HER2-positive breast cancer.

Maurie Markman, MD, discusses an analysis of the association between obesity and the development of endometrial cancer.

Sam Brondfield, MD, MA, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses careers in medical education.

Ciara Kelly, MBBCh, BAO, discusses the current and potential roles for ripretinib in the gastrointestinal stromal tumor treatment paradigm.

Mark Agulnik, MD, discusses the evolving management of heterogeneous disease types in gastrointestinal stromal tumors.

Lova Sun, MD, MSCE, discussions safety implications observed from part C of the phase 2 innovaTV 207 trial.

Jerôme Fayette, MD, PhD, discusses findings from a trial of frontline petosemtamab plus pembrolizumab in patients with recurrent/metastatic HNSCC.

Jun Gong, MD, discusses the importance of molecular profiling when determining optimal treatments for patients with mCRPC.

Rebecca Klisovic, MD, discusses the early use of JAK inhibitors to treat younger patients with low-risk, newly diagnosed myelofibrosis.

Kedar Kirtane, MD, discusses the design of a phase 1b trial evaluating the TIL Tbio-4101 plus pembrolizumab in patients with advanced HNSCC.